May 18, 2023
Pacylex Pharmaceuticals Announces First Patient Dosed in a Phase 2a Study of PCLX-001 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
![](https://assets-global.website-files.com/651719eb96e2a4ad7cf6538c/65187eb75231fb3f86f4571b_icons8-right-arrow-48%20(1).png)
The first patient has been dosed with PCLX-001 monotherapy, a first-in-class, oral small molecule N-myristoyltransferase (NMT) inhibitor, in a Phase 2a expansion study.
The expansion study will enroll up to 20 patients.